Prothena Corp. plc Stock
Prothena Corp. plc Stock
A loss of -2.780% shows a downward development for Prothena Corp. plc.
Prothena Corp. plc is currently one of the favorites of our community with 13 Buy predictions and no Sell predictions.
Based on the current price of 20.4 € the target price of 80 € shows a potential of 292.16% for Prothena Corp. plc which would more than double the current price.
Pros and Cons of Prothena Corp. plc in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Prothena Corp. plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Prothena Corp. plc | -2.780% | 4.615% | -6.422% | -70.647% | -41.379% | -1.923% | - |
| Ardelyx Inc. | -3.830% | 19.664% | 14.204% | 98.895% | 30.761% | 36.180% | - |
| Evolus Inc | -1.650% | 2.542% | 0.000% | 47.561% | 33.702% | 64.626% | - |
| Salarius Pharmaceuticals Inc. | 2.480% | -12.174% | -6.047% | -77.430% | -27.207% | -98.343% | -99.993% |
Comments
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at HC Wainwright from $90.00 to $84.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PRTA provided by MarketBeat
Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for PRTA provided by MarketBeat
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Show more
Ratings data for PRTA provided by MarketBeat